Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 1/20 | 0.40 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.34 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.34 |
| ▸ | NSD2 | O96028 | 2/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | EHMT2 | Q96KQ7 | 4/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.32 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.31 |
| ▸ | CD38 | P28907 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10190151 | 1.00 | PIK3CA (0.40) | PIK3CARIPK2SIGMAR1BRD4ATAD2 | |
| SCHEMBL601155 | 0.87 | PIK3CA (0.36) | PIK3CARIPK2SIGMAR1PDE7ANSD2 | |
| SCHEMBL601154 | 0.87 | PIK3CA (0.36) | PIK3CARIPK2SIGMAR1PDE7ANSD2 | |
| SCHEMBL601375 | 0.87 | PIK3CA (0.36) | PIK3CARIPK2SIGMAR1PDE7ANSD2 | |
| SCHEMBL14213276 | 0.86 | PIK3CA (0.36) | PIK3CABRD4ATAD2NSD2EHMT2 | |
| SCHEMBL602458 | 0.84 | ALOX15 (0.35) | PIK3CASIGMAR1BRD4ATAD2NSD2 | |
| SCHEMBL602459 | 0.84 | ALOX15 (0.35) | PIK3CASIGMAR1BRD4ATAD2NSD2 | |
| SCHEMBL600951 | 0.84 | RIPK2 (0.35) | PIK3CARIPK2BRD4ATAD2PDE7A | |
| SCHEMBL601474 | 0.84 | RIPK2 (0.35) | PIK3CARIPK2BRD4ATAD2PDE7A | |
| SCHEMBL600181 | 0.84 | IRAK4 (0.39) | PIK3CARIPK2BRD4ATAD2PDE7A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120309789-A1 | Compounds which have activity at M1 receptor and their uses in medicine | GLAXO GROUP LIMITED | 2012-12-06 | — | — | US | disclosed |
| US-20120041027-A1 | BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LIMITED | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120041027-A1 | BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | CHRM1, CHRM2, CHRM4 | PIK3CA 2820/4885RIPK2 3830/4885SIGMAR1 20/4885 |
| US-20120309789-A1 | Compounds which have activity at M1 receptor and their uses in medicine | CHRM1, CHRM2, CHRM5 | PIK3CA 2838/4885RIPK2 3399/4885SIGMAR1 72/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.